Skip to main content
SpringerLink
Log in

Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future

  • Chapter
Therapeutic Antibodies

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 181))

Tumor necrosis factor alpha (TNF) is an important cell-signaling component of the immune system. Since its discovery over 20 years ago, much has been learned about its functions under normal and disease conditions. Nonclinical studies suggested a role for TNF in chronic immune-mediated inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis, and therefore neutralizing monoclonal antibodies specific to human TNF were developed for clinical evaluation. Treatment with anti-TNF monoclonal antibodies (infliximab, adalimumab, and certolizumab pegol) has been shown to provide substantial benefit to patients through reductions in both localized and systemic expression of markers associated with inflammation. In addition, there are beneficial effects of anti-TNF treatment on markers of bone and cartilage turnover. Further exploration of changes in these markers and their correlation with clinical measures of efficacy will be required to allow accurate prediction of those patients most in need of these treatments. Both the clinical and commercial experience with these anti-TNF antibodies provide a wealth of information regarding their pharmacological effects in humans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aeberli D, Seitz M, Juni P, Villiger PM (2005) Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford) 44:172-175

    CAS  Google Scholar 

  • Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3:745-756

    PubMed  CAS  Google Scholar 

  • Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN (1985) Human tumor necrosis factor. Production, purification, and characterization. J Biol Chem 260:2345-2354

    PubMed  CAS  Google Scholar 

  • Agnholt J, Kaltoft K (2001) Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn’s disease. Cytokine 15:212-222

    PubMed  CAS  Google Scholar 

  • Ahmed MM, Mubashir E, Wolf RE, Hayat S, Hall V, Shi R, Berney SM (2006) Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. South Med J 99:1209-1215

    PubMed  Google Scholar 

  • Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G (2004) Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following antiTNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 63:1218-1221

    PubMed  CAS  Google Scholar 

  • Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B (2002) Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 47:506-512

    PubMed  CAS  Google Scholar 

  • Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305-1308

    PubMed  CAS  Google Scholar 

  • Atzeni F, Sarzi-Puttini P, Dell’ Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 8:R3

    PubMed  Google Scholar 

  • Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 116:22-28

    PubMed  CAS  Google Scholar 

  • Baeten D, Van Damme N, Van den Bosch F, Kruithof E, De Vos M, Mielants H, Veys EM, De Keyser F (2001) Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 60:750-755

    PubMed  CAS  Google Scholar 

  • Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS (2003) Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease. Am J Gastroenterol 98:833-838

    PubMed  CAS  Google Scholar 

  • Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11:372-377

    PubMed  CAS  Google Scholar 

  • Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717-1725

    PubMed  CAS  Google Scholar 

  • Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, Ulevitch R, Cerami A (1985a) Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552-554

    CAS  Google Scholar 

  • Beutler B, Milsark IW, Cerami AC (1985b) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871

    CAS  Google Scholar 

  • Bevilacqua MP, Gimbrone MA, Jr. (1987) Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 13:425-433

    PubMed  CAS  Google Scholar 

  • Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729-733

    PubMed  CAS  Google Scholar 

  • Bodmer M, Fournel MA, Hinshaw LB (1993) Preclinical review of anti-tumor necrosis factor monoclonal antibodies. Crit Care Med 21:S441-S446

    PubMed  CAS  Google Scholar 

  • Boyce BF, Schwarz EM, Xing L (2006) Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr Opin Rheumatol 18:427-432

    PubMed  CAS  Google Scholar 

  • Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO (2004) Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199: 731-736

    PubMed  CAS  Google Scholar 

  • Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1352

    PubMed  CAS  Google Scholar 

  • Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Sieper J (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229-234

    PubMed  CAS  Google Scholar 

  • Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33:497-500

    PubMed  CAS  Google Scholar 

  • Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M (1997) Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 36:643-650

    PubMed  CAS  Google Scholar 

  • Briot K, Garnero P, Le Henanff A, Dougados M, Roux C (2005) Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 64:1137-1140

    PubMed  CAS  Google Scholar 

  • Bunning RA, Russell RG (1989) The effect of tumor necrosis factor alpha and gamma-interferon on the resorption of human articular cartilage and on the production of prostaglandin E and of caseinase activity by human articular chondrocytes. Arthritis Rheum 32:780-784

    PubMed  CAS  Google Scholar 

  • Burke F (1999) Cytokines (IFNs, TNF-alpha, IL-2 and IL-12) and animal models of cancer. Cytokines Cell Mol Ther 5:51-61

    PubMed  CAS  Google Scholar 

  • Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666-3670

    PubMed  CAS  Google Scholar 

  • Cauza E, Hanusch-Enserer U, Frischmuth K, Fabian B, Dunky A, Kostner K (2006) Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. J Clin Pharm Ther 31:149-152

    PubMed  CAS  Google Scholar 

  • Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN (1999) Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 163:1521-1528

    PubMed  CAS  Google Scholar 

  • Chen DM, Gordon KB, Leonardi C, Menter MA (2004) Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: Preliminary findings from a 12-week dose ranging trial. J Am Acad Dermatol 50:Suppl:P2

    Google Scholar 

  • Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG, Patel J, Sopwith M, Isenberg DA (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41:1133-1137

    CAS  Google Scholar 

  • Clark M (2000) Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol Today 21:397-402

    PubMed  CAS  Google Scholar 

  • Cornillie F, Shealy D, D’Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P (2001) Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease. Aliment Pharmacol Ther 15: 463-473

    PubMed  CAS  Google Scholar 

  • Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, Gatica H, Schiattino I, Perez C, Aguirre A, Salazar-Onfray F, Aguillon JC (2004) Tumour necrosis factor-alpha (TNF-alpha) levels and influence of −308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol 33:228-232

    PubMed  CAS  Google Scholar 

  • den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H (2002a) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29:2288-2298

    CAS  Google Scholar 

  • den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM, Frasa WL, van Tits LJ, Buurman WA, van Riel PL, van de Putte LB, Barrera P (2002b) Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 61:311-318

    CAS  Google Scholar 

  • den Broeder AA, Wanten GJ, Oyen WJ, Naber T, van Riel PL, Barrera P (2003) Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol 30:232-237

    PubMed  CAS  Google Scholar 

  • Detkova Z, Kupcova V, Prikazska M, Turecky L, Weissova S, Jahnova E (2003) Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn’s disease. Physiol Res 52:95-100

    PubMed  CAS  Google Scholar 

  • Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 200:277-285

    PubMed  CAS  Google Scholar 

  • Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G (2002) Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 29:1847-1850

    PubMed  CAS  Google Scholar 

  • Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA (2000) Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterol 95:3490-3497

    PubMed  CAS  Google Scholar 

  • Fasanmade AA, Zhu YW, Wagner C, Pendley C, Davis HM (2002) Population pharmacokinetics of single dose infliximab in patients with Crohn’s disease. Clin Pharmacol Ther 71:P66

    Google Scholar 

  • Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN (2004) Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp 256: 53-69; discussion 69-73, 106-111, 266-109

    PubMed  CAS  Google Scholar 

  • Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19:163-196

    PubMed  CAS  Google Scholar 

  • Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD (2004) Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63:156-161

    PubMed  CAS  Google Scholar 

  • Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572

    PubMed  CAS  Google Scholar 

  • Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E (2004) Rapid improvement of bone metabolism after infliximab treatment in Crohn’s disease. Aliment Pharmacol Ther 20:607-614

    PubMed  CAS  Google Scholar 

  • Freeman BD, Natanson C (2000) Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 9:1651-1663

    PubMed  CAS  Google Scholar 

  • Gao Q, Hogezand RA, Lamers CB, Verspaget HW (2004) Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn’s disease. Aliment Pharmacol Ther 20:585-592

    PubMed  Google Scholar 

  • Gao Q, Meijer MJ, Schluter UG, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW (2007) Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and −9 in Crohn’s disease. Inflamm Bowel Dis 13(6):693-702

    PubMed  Google Scholar 

  • Garfield BE, Krahl T, Appel S, Cooper SM, Rincon M (2005) Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis. Clin Immunol 116:101-107

    PubMed  CAS  Google Scholar 

  • Geboes K, Dalle I (2002) Influence of treatment on morphological features of mucosal inflammation. Gut 50(Suppl 3):III37-III42

    PubMed  Google Scholar 

  • Georgopoulos S, Plows D, Kollias G (1996) Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 46:86-97

    PubMed  CAS  Google Scholar 

  • Goldstein G, Fuccello AJ, Norman DJ, Shield CF, 3rd, Colvin RB, Cosimi AB (1986) OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 42:507-511

    PubMed  CAS  Google Scholar 

  • Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J (2006) Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. Clin Exp Rheumatol 24:373-379

    PubMed  CAS  Google Scholar 

  • Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, Dooley LT, Fasanmade AA, Wagner CL (2003) Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48:68-75

    PubMed  Google Scholar 

  • Grell M, Becke FM, Wajant H, Mannel DN, Scheurich P (1998) TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol 28:257-263

    PubMed  CAS  Google Scholar 

  • Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P (1995) The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83:793-802

    PubMed  CAS  Google Scholar 

  • Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Deviere J, Franchimont D (2005) Profile of soluble cytokine receptors in Crohn’s disease. Gut 54: 488-495

    PubMed  CAS  Google Scholar 

  • Haridas V, Darnay BG, Natarajan K, Heller R, Aggarwal BB (1998) Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol 160:3152-3162

    PubMed  CAS  Google Scholar 

  • Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126-1136

    PubMed  CAS  Google Scholar 

  • Janelsins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ (2005) Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer’s disease mice. J Neuroinflammation 2:23

    PubMed  Google Scholar 

  • Jelinek DF, Lipsky PE (1987) Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J Immunol 139:2970-2976

    PubMed  CAS  Google Scholar 

  • Kageyama Y, Torikai E, Nagano A (2007) Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. Rheumatol Int 27:467-472

    PubMed  CAS  Google Scholar 

  • Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759

    PubMed  CAS  Google Scholar 

  • Kaushik VV, Moots RJ (2005) CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther 5:601-606

    PubMed  CAS  Google Scholar 

  • Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 10:4025-4031

    PubMed  CAS  Google Scholar 

  • Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J (2004) Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. J Rheumatol 31:238-242

    PubMed  CAS  Google Scholar 

  • Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al. (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453

    PubMed  CAS  Google Scholar 

  • Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Fass DN, Coller BS, Weisman HF, Ghrayeb J (1995) The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 32:1271-1281

    PubMed  CAS  Google Scholar 

  • Koch AE, Kunkel SL, Strieter RM (1995) Cytokines in rheumatoid arthritis. J Investig Med 43: 28-38

    PubMed  CAS  Google Scholar 

  • Kollias G (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34:3-6

    PubMed  CAS  Google Scholar 

  • Korner H, Cook M, Riminton DS, Lemckert FA, Hoek RM, Ledermann B, Kontgen F, Fazekas de St Groth B, Sedgwick JD (1997) Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur J Immunol 27:2600-2609

    PubMed  CAS  Google Scholar 

  • Korzenik JR, Podolsky DK (2006) Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov 5:197-209

    PubMed  CAS  Google Scholar 

  • Krejsa C, Rogge M, Sadee W (2006) Protein therapeutics: new applications for pharmacogenetics. Nat Rev Drug Discov 5:507-521

    PubMed  CAS  Google Scholar 

  • Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82:434-448

    PubMed  CAS  Google Scholar 

  • Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M (2006) Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. Ann Rheum Dis 65:26-29

    PubMed  CAS  Google Scholar 

  • Lange U, Teichmann J, Muller-Ladner U, Strunk J (2005) Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective openlabel pilot study. Rheumatology (Oxford) 44:1546-1548

    CAS  Google Scholar 

  • Legler DF, Micheau O, Doucey MA, Tschopp J, Bron C (2003) Recruitment of TNF receptor 1 to lipid rafts is essential for TNFalpha-mediated NF-kappaB activation. Immunity 18:655-664

    PubMed  CAS  Google Scholar 

  • Lejeune FJ, Lienard D, Matter M, Ruegg C (2006) Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 6:6

    PubMed  Google Scholar 

  • Lequerre T, Gauthier-Jauneau AC, Bansard C, Derambure C, Hiron M, Vittecoq O, Daveau M, Mejjad O, Daragon A, Tron F, Le Loet X, Salier JP (2006) Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 8:R105

    PubMed  Google Scholar 

  • Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594-1602

    PubMed  CAS  Google Scholar 

  • Lonberg N (2005) Human antibodies from transgenic animals. Nat Biotechnol 23:1117-1125

    PubMed  CAS  Google Scholar 

  • Louis E, El Ghoul Z, Vermeire S, Dall’Ozzo S, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Colombel JF, Watier H (2004) Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther 19:511-519

    PubMed  CAS  Google Scholar 

  • Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T (2001) Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology 121:1145-1157

    PubMed  CAS  Google Scholar 

  • Malik ST, Naylor MS, East N, Oliff A, Balkwill FR (1990) Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 26:1031-1034

    PubMed  CAS  Google Scholar 

  • Mandl T, Jacobsson L (2002) [Anti-TNF-α treatment-an effective complement in spondyloarthropathy]. Lakartidningen 99:5189-5193

    PubMed  Google Scholar 

  • Marini M, Bamias G, Rivera-Nieves J, Moskaluk CA, Hoang SB, Ross WG, Pizarro TT, Cominelli F (2003) TNF-alpha neutralization ameliorates the severity of murine Crohn’s-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci USA 100: 8366-8371

    PubMed  CAS  Google Scholar 

  • Marino MW, Dunn A, Grail D, Inglese M, Noguchi Y, Richards E, Jungbluth A, Wada H, Moore M, Williamson B, Basu S, Old LJ (1997) Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 94:8093-8098

    PubMed  CAS  Google Scholar 

  • Markham A, Lamb HM (2000) Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59:1341-1359

    PubMed  CAS  Google Scholar 

  • Martinez A, Salido M, Bonilla G, Pascual-Salcedo D, Fernandez-Arquero M, de Miguel S, Balsa A, de la Concha EG, Fernandez-Gutierrez B (2004) Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 50:1077-1082

    PubMed  CAS  Google Scholar 

  • Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D’Agosto G, Cordiali-Fei P, Berardesca E (2005) Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 153:531-536

    PubMed  CAS  Google Scholar 

  • Meyer O, Labarre C, Dougados M, Goupille P, Cantagrel A, Dubois A, Nicaise-Roland P, Sibilia J, Combe B (2003) Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 62:120-126

    PubMed  CAS  Google Scholar 

  • Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114:181-190

    PubMed  CAS  Google Scholar 

  • Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, Holdsworth H, Turner L, Rollins B, Pasparakis M, Kollias G, Balkwill F (1999) Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 5:828-831

    PubMed  CAS  Google Scholar 

  • Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD, et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385:733-736

    PubMed  CAS  Google Scholar 

  • Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D (2003) Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 48:1849-1852

    PubMed  CAS  Google Scholar 

  • Mullin JM, Snock KV (1990) Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 50:2172-2176

    PubMed  CAS  Google Scholar 

  • Myers WA, Gottlieb AB, Mease P (2006) Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 24:438-447

    PubMed  Google Scholar 

  • Nadkarni S, Mauri C, Ehrenstein MR (2007) Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 204:33-39

    PubMed  CAS  Google Scholar 

  • Nakada MT, Tam SH, Woulfe DS, Casper KA, Swerlick RA, Ghrayeb J (1998) Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhes Commun 5:491-503

    PubMed  CAS  Google Scholar 

  • Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum 34:12-18

    PubMed  CAS  Google Scholar 

  • Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, Strober W, Kollias G (1997) Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 27:1743-1750

    PubMed  CAS  Google Scholar 

  • Osbourn J, Groves M, Vaughan T (2005) From rodent reagents to human therapeutics using antibody guided selection. Methods 36:61-68

    PubMed  CAS  Google Scholar 

  • Pasparakis M, Alexopoulou L, Episkopou V, Kollias G (1996) Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med 184:1397-1411

    PubMed  CAS  Google Scholar 

  • Passeri G, Girasole G, Manolagas SC, Jilka RL (1994) Endogenous production of tumor necrosis factor by primary cultures of murine calvarial cells: influence on IL-6 production and osteoclast development. Bone Miner 24:109-126

    PubMed  CAS  Google Scholar 

  • Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312:724-729

    PubMed  CAS  Google Scholar 

  • Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M (1990) A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251-258

    PubMed  CAS  Google Scholar 

  • Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W (1992) Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77:510-514

    PubMed  CAS  Google Scholar 

  • Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431:461-466

    PubMed  CAS  Google Scholar 

  • Pittoni V, Bombardieri M, Spinelli FR, Scrivo R, Alessandri C, Conti F, Spadaro A, Valesini G (2002) Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 61:723-725

    PubMed  CAS  Google Scholar 

  • Pizarro TT, Arseneau KO, Bamias G, Cominelli F (2003) Mouse models for the study of Crohn’s disease. Trends Mol Med 9:218-222

    PubMed  CAS  Google Scholar 

  • Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR (1997) A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 159:6276-6282

    PubMed  CAS  Google Scholar 

  • Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL (1994) Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1:553-562

    PubMed  CAS  Google Scholar 

  • Rajpal A, Beyaz N, Haber L, Cappuccilli G, Yee H, Bhatt RR, Takeuchi T, Lerner RA, Crea R (2005) A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci USA 102:8466-8471

    PubMed  CAS  Google Scholar 

  • Ranganathan P (2005) Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis. Pharmacogenomics 6:481-490

    PubMed  CAS  Google Scholar 

  • Rose-John S, Schooltink H (2003) CDP-870. Celltech/Pfizer. Curr Opin Investig Drugs 4:588-592

    PubMed  CAS  Google Scholar 

  • Rothe M, Wong SC, Henzel WJ, Goeddel DV (1994) A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78:681-692

    PubMed  CAS  Google Scholar 

  • Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462-2476

    PubMed  CAS  Google Scholar 

  • Sadowsky DW, Adams KM, Gravett MG, Witkin SS, Novy MJ (2006) Preterm labor is induced by intraamniotic infusions of interleukin-1beta and tumor necrosis factor-alpha but not by interleukin-6 or interleukin-8 in a nonhuman primate model. Am J Obstet Gynecol 195:1578-1589

    PubMed  Google Scholar 

  • Saklatvala J (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 322:547-549

    PubMed  CAS  Google Scholar 

  • Salfeld J, Allen D, Hoogenboom HR, Kaymakcalan Z, Labkovsky B, Mankovich J, McGuinness B, Roberts A, Sakorafas P, Schoenhaut D, Vaughan T, White M, Wilton A (2000) Human antibodies that bind human TNF alpha. US Patent 6,090,382

    Google Scholar 

  • Santora LC, Kaymakcalan Z, Sakorafas P, Krull IS, Grant K (2001) Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. Anal Biochem 299:119-129

    PubMed  CAS  Google Scholar 

  • Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426

    PubMed  CAS  Google Scholar 

  • Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7:251-259

    PubMed  CAS  Google Scholar 

  • Scheinfeld N (2004) Off-label uses and side effects of infliximab. J Drugs Dermatol 3:273-284

    PubMed  Google Scholar 

  • Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M (2003) Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 133:38-43

    PubMed  CAS  Google Scholar 

  • Scheurich P, Thoma B, Ucer U, Pfizenmaier K (1987) Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses. J Immunol 138:1786-1790

    PubMed  CAS  Google Scholar 

  • Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OO, Innes A (2005) A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology 129:807-818

    PubMed  CAS  Google Scholar 

  • Schutze S, Machleidt T, Adam D, Schwandner R, Wiegmann K, Kruse ML, Heinrich M, Wickel M, Kronke M (1999) Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signaling. J Biol Chem 274:10203-10212

    PubMed  Google Scholar 

  • Schwab M, Klotz U (2001) Pharmacokinetic considerations in the treatment of inflammatory bowel disease. Clin Pharmacokinet 40:723-751

    PubMed  CAS  Google Scholar 

  • Scott KA, Moore RJ, Arnott CH, East N, Thompson RG, Scallon BJ, Shealy DJ, Balkwill FR (2003) An anti-tumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2:445-451

    PubMed  CAS  Google Scholar 

  • Seko Y, Cole S, Kasprzak W, Shapiro BA, Ragheb JA (2006) The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev 5:299-305

    PubMed  CAS  Google Scholar 

  • Semmler M, Seeck U, Neustadt B, Schulz M, Dotzlaw H, Neeck G, Eggert M (2007) No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. Clin Rheumatol 26:1499-1504

    PubMed  Google Scholar 

  • Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, Wagner CL, Mayton L, Griswold DE, Song XY (2002) Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice. Arthritis Res 4:R7

    PubMed  Google Scholar 

  • Smith RA, Baglioni C (1987) The active form of tumor necrosis factor is a trimer. J Biol Chem 262:6951-6954

    PubMed  CAS  Google Scholar 

  • Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52:1020-1030

    PubMed  CAS  Google Scholar 

  • Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Maini RN, Kalden JR, Schiff M, Baker D, Han C, Han J, Bala M (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54:702-710

    PubMed  CAS  Google Scholar 

  • St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50:3432-3443

    PubMed  CAS  Google Scholar 

  • St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC (2002) The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1451-1459

    PubMed  CAS  Google Scholar 

  • Strand V, Kimberly R, Isaacs JD (2007) Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6:75-92

    PubMed  CAS  Google Scholar 

  • Strunk J, Bundke E, Lange U (2006) Anti-TNF-alpha antibody Infliximab and glucocorticoids reduce serum vascular endothelial growth factor levels in patients with rheumatoid arthritis: a pilot study. Rheumatol Int 26:252-256

    PubMed  CAS  Google Scholar 

  • Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM (1985) Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230:943-945

    PubMed  CAS  Google Scholar 

  • Szlosarek P, Charles KA, Balkwill FR (2006) Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 42:745-750

    PubMed  CAS  Google Scholar 

  • Tchetverikov I, Lohmander LS, Verzijl N, Huizinga TW, TeKoppele JM, Hanemaaijer R, DeGroot J (2005) MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 64:694-698

    PubMed  CAS  Google Scholar 

  • ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ (2002) Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 50:206-211

    PubMed  CAS  Google Scholar 

  • Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA (1992) Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 89:7375-7379

    PubMed  CAS  Google Scholar 

  • Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A (2007) The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 26(7):1088-1093

    PubMed  Google Scholar 

  • Torikai E, Kageyama Y, Takahashi M, Suzuki M, Ichikawa T, Nagafusa T, Nagano A (2006) The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. Rheumatology (Oxford) 45:761-764

    CAS  Google Scholar 

  • Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, 3rd, Zentella A, Albert JD, et al. (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474

    PubMed  CAS  Google Scholar 

  • Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC (2000) Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 43:2391-2396

    PubMed  CAS  Google Scholar 

  • Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE (2006) TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 108:253-261

    PubMed  CAS  Google Scholar 

  • Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124:1774-1785

    PubMed  CAS  Google Scholar 

  • Van den Brande JM, Koehler T, Zelinkova Z, Bennink RJ, Te Velde AA, Ten Kate F, van Deventer SJ, Peppelenbosch MP, Hommes DW (2006) Prediction of anti-TNF clinical efficacy by realtime visualisation of apoptosis in patients with Crohn’s disease. Gut 56(4):461-463

    Google Scholar 

  • van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591

    PubMed  CAS  Google Scholar 

  • van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J (1995) Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135

    PubMed  CAS  Google Scholar 

  • van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM (2005) Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. Ann Rheum Dis 64:537-543

    PubMed  CAS  Google Scholar 

  • van Roon JA, Hartgring SA, Wenting-van Wijk M, Jacobs KM, Tak PP, Bijlsma JW, Lafeber FP (2007) Persistence of IL-7 activity and IL-7 levels upon TNFα blockade in patients with rheumatoid arthritis. Ann Rheum Dis 66:664-669

    PubMed  CAS  Google Scholar 

  • Vandooren B, Kruithof E, Yu DT, Rihl M, Gu J, De Rycke L, Van Den Bosch F, Veys EM, De Keyser F, Baeten D (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942-2953

    PubMed  CAS  Google Scholar 

  • Velagapudi RB, Noertersheuser PA, Awni WM, Fischkoff SA, Kupper H, Granneman GR, van de Putte LBA, Keystone EC (2003) Effect of methotrexate coadministration on the pharmacokinetics of Adaliumab (Humira, Abbott) following a single intravenous injection. Arthritis Rheum 51(Suppl):S141

    Google Scholar 

  • Vespasiani Gentilucci U, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, Petitti T, Afeltra A, Cicala M (2005) Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 21:1063-1071

    PubMed  CAS  Google Scholar 

  • Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495-1499

    PubMed  CAS  Google Scholar 

  • Visvanathan S, Marano C, Braun J, Kavanaugh A, Yan S, Gathany T, Han J, Zhou B, Baker D, Wagner C (2006) Comparison of the effect of infliximab on inflammation and bone formation biomarkes and associations with clinical response in ankylosing spondylitis and psoriatic arthritis. Arthritis Rheum 54(Suppl):S792

    Google Scholar 

  • Visvanathan S, Marini JC, Smolen JS, St Clair EW, Pritchard C, Shergy W, Pendley C, Baker D, Bala M, Gathany T, Wagner C (2007a) Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 34:1465-1474

    CAS  Google Scholar 

  • Visvanathan S, Wagner C, Marini JC, van der Heijde D, Baker D, Gathany T, Han J, Braun J (2007b) Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis doi:10.1136/ard.2007.071605

    Google Scholar 

  • Watkins PE, Warren BF, Stephens S, Ward P, Foulkes R (1997) Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha. Gut 40:628-633

    PubMed  CAS  Google Scholar 

  • Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784-9788

    PubMed  CAS  Google Scholar 

  • Willot S, Vermeire S, Ohresser M, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Franchimont D, Colombel JF, Watier H, Louis E (2006) No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn’s disease. Pharmacogenet Genomics 16:37-42

    PubMed  CAS  Google Scholar 

  • Xu Z, Fasanmade A, Pendley C, Williamson P, Xu W, Jang H, Davis HM, Zhou H (2006) Population pharmacokinetics of infliximab, an anti-tumor necrosis factor-alpha monoclonal antibody in patients with ankylosing spondylitis: a randomized double blind Phase III trial. Arthritis Rheum 54(Suppl):S475

    Google Scholar 

  • Zhang YH, Lin JX, Vilcek J (1990) Interleukin-6 induction by tumor necrosis factor and interleukin-1 in human fibroblasts involves activation of a nuclear factor binding to a kappa B-like sequence. Mol Cell Biol 10:3818-3823

    PubMed  CAS  Google Scholar 

  • Zhu Y, Menter A, Jang H, Zhou H (2006) Pharmacokinetics and Pharmacodynamics of Infliximab in a Phase III Trial in Patients with Plaque-type Psoriasis American Academy of Dermatology, San Francisco, CA

    Google Scholar 

  • Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J (2003) Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 48:780-790

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centocor Research and Development, Inc., 145 King of Prussia Road, Radnor, PA 19087

    D. J. Shealy & S. Visvanathan

Authors
  1. D. J. Shealy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Visvanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ARC Chair of Rheumatology, Centre Lead Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre, Charterhouse Square, EC1M 6BQ, London, UK

    Yuti Chernajovsky

  2. Bone & Joint Research Unit, Queen Mary's School of Medicine & Dentistry John Vane Science Centre, Charterhouse Square, EC1M 6BQ, London, UK

    Ahuva Nissim

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Shealy, D.J., Visvanathan, S. (2008). Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future. In: Chernajovsky, Y., Nissim, A. (eds) Therapeutic Antibodies. Handbook of Experimental Pharmacology, vol 181. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-73259-4_5

Download citation

Publish with us

Policies and ethics

Search

Navigation